Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting
G. Curigliano, M. De Laurentiis, N. Harbeck, S. Kuemmel, J.Á. García-Sáenz, R. Sanchez Bayona, D. Rea, A. Okines, B. Pistilli, E. Sears, J. Maitland, S. Kloss, T. Wasserman, M. Ignatiadis · 2026
Read Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting by G. Curigliano, M. De Laurentiis, N. Harbeck, S. Kuemmel, J.Á. García-Sáenz, R. Sanchez Bayona, D. Rea, A. Okines, B. Pistilli, E. Sears, J. Maitland, S. Kloss, T. Wasserman, M. Ignatiadis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594719.txt.
Description
Giuseppe Curigliano and co-authors reported in 2026 how a targeted hormone pill performs in everyday practice for advanced breast cancer carrying a specific receptor mutation. Their cohort held 281 patients who had already received hormone therapy plus a cell-cycle drug. Records came from insurance claims linked with genomic testing data.
The yardstick was time until the next treatment began, a stand-in for how long the pill held the disease. Patients with one or two prior lines stayed on it about eight months. Those whose earlier therapy had lasted at least a year did better, near nine to twelve months. Spread to liver, lung, or brain shortened the benefit somewhat. The authors call the results durable and back the pill as a first choice for suitable tumors.
Catalog record
| CREATOR | G. Curigliano, M. De Laurentiis, N. Harbeck, S. Kuemmel, J.Á. García-Sáenz, R. Sanchez Bayona, D. Rea, A. Okines, B. Pistilli, E. Sears, J. Maitland, S. Kloss, T. Wasserman, M. Ignatiadis |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |